REDHILL BIOPHAR/S (RDHL) Cut to Hold at Zacks Investment Research
Zacks Investment Research lowered shares of REDHILL BIOPHAR/S (NASDAQ:RDHL) from a buy rating to a hold rating in a research report report published on Tuesday.
According to Zacks, “Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools. Its clinical-stage pipeline includes: TALICIA (RHB-105), an oral combination therapy for the treatment of Helicobacter pylori infection; RHB-104, an oral combination therapy for the treatment of Crohn’s disease; BEKINDA (RHB-102), a once-daily oral pill formulation of ondansetron; RHB-106; YELIVA (ABC294640); MESUPRON, and RIZAPORT (RHB-103). “
Other equities research analysts also recently issued reports about the stock. HC Wainwright reaffirmed a buy rating on shares of REDHILL BIOPHAR/S in a research note on Tuesday, July 31st. ValuEngine raised shares of REDHILL BIOPHAR/S from a sell rating to a hold rating in a research note on Wednesday, October 3rd. One equities research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of Buy and an average target price of $20.65.
REDHILL BIOPHAR/S (NASDAQ:RDHL) last announced its earnings results on Thursday, August 30th. The biotechnology company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.05). REDHILL BIOPHAR/S had a negative return on equity of 133.07% and a negative net margin of 564.71%. The business had revenue of $2.35 million for the quarter, compared to analysts’ expectations of $2.77 million. As a group, research analysts predict that REDHILL BIOPHAR/S will post -1.69 earnings per share for the current year.
Large investors have recently made changes to their positions in the business. 683 Capital Management LLC increased its position in shares of REDHILL BIOPHAR/S by 22.8% in the 2nd quarter. 683 Capital Management LLC now owns 2,042,654 shares of the biotechnology company’s stock valued at $17,424,000 after purchasing an additional 378,751 shares during the last quarter. Clear Harbor Asset Management LLC purchased a new stake in shares of REDHILL BIOPHAR/S in the 3rd quarter valued at approximately $323,000. ARK Investment Management LLC increased its position in shares of REDHILL BIOPHAR/S by 8.6% in the 2nd quarter. ARK Investment Management LLC now owns 112,648 shares of the biotechnology company’s stock valued at $961,000 after purchasing an additional 8,894 shares during the last quarter. Creative Planning increased its position in shares of REDHILL BIOPHAR/S by 16.1% in the 3rd quarter. Creative Planning now owns 162,950 shares of the biotechnology company’s stock valued at $1,439,000 after purchasing an additional 22,561 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its position in shares of REDHILL BIOPHAR/S by 61.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 73,878 shares of the biotechnology company’s stock valued at $652,000 after purchasing an additional 28,102 shares during the last quarter. 22.80% of the stock is currently owned by institutional investors.
About REDHILL BIOPHAR/S
RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of late clinical-stage drugs for the treatment of gastrointestinal diseases. It commercializes and promotes gastrointestinal products in the United States. The company's pipeline includes various drug candidates that are in advanced clinical development stages, including three Phase III-stage programs.
Featured Article: What does earnings per share mean?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for REDHILL BIOPHAR/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REDHILL BIOPHAR/S and related companies with MarketBeat.com's FREE daily email newsletter.